Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.68 |
| ▸ | CNR1 | P21554 | 1/20 | 0.68 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.68 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.68 |
| ▸ | GABRA1 | P14867 | 7/20 | 0.67 |
| ▸ | GABRA5 | P31644 | 7/20 | 0.67 |
| ▸ | GABRA3 | P34903 | 7/20 | 0.67 |
| ▸ | GABRA2 | P47869 | 7/20 | 0.67 |
| ▸ | GABRB2 | P47870 | 6/20 | 0.67 |
| ▸ | GABRG2 | P18507 | 5/20 | 0.67 |
| ▸ | GABRB3 | P28472 | 5/20 | 0.67 |
| ▸ | GABRP | O00591 | 3/20 | 0.67 |
| ▸ | GABRD | O14764 | 3/20 | 0.67 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.67 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.67 |
| ▸ | GABRE | P78334 | 3/20 | 0.67 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.67 |
| ▸ | GABRG1 | Q8N1C3 | 3/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30289323 | 1.00 | KMT2A (1.00) | KMT2AMEN1PDE4DCNR1NTSR1 | |
| SCHEMBL9686097 | 0.86 | MEN1 (0.75) | KMT2AMEN1PDE4DCNR1NTSR1 | |
| SCHEMBL30297595 | 0.84 | KMT2A (0.73) | KMT2AMEN1PDE4DCNR1NTSR1 | |
| SCHEMBL9563515 | 0.84 | KMT2A (0.73) | KMT2AMEN1PDE4DCNR1NTSR1 | |
| SCHEMBL9563509 | 0.84 | KMT2A (0.73) | KMT2AMEN1PDE4DCNR1NTSR1 | |
| SCHEMBL23424295 | 0.84 | KMT2A (0.73) | KMT2AMEN1PDE4DCNR1NTSR1 | |
| SCHEMBL9422490 | 0.84 | KMT2A (0.73) | KMT2AMEN1PDE4DCNR1NTSR1 | |
| SCHEMBL15400204 | 0.84 | KMT2A (0.72) | KMT2AMEN1PDE4DCNR1NTSR1 | |
| SCHEMBL9684191 | 0.83 | KMT2A (0.71) | KMT2AMEN1PDE4DCNR1NTSR1 | |
| Ro-24-7429 SCHEMBL29736766 | 0.83 | MEN1 (0.70) | KMT2AMEN1PDE4DCNR1NTSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12613236-B2 | Lung fibrosis model and methods of using the same | DUKE UNIVERSITY (US) | 2026-04-28 | — | — | US | claimed |
| US-20250325717-A1 | ANTI-NUCLEOPHOSMIN 1 ANTIBODY AND ANTIBODY CONJUGATE COMBINATION THERAPIES | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-10-23 | — | — | US | claimed |
| US-12440443-B2 | Nano-emulsion of CBFβ-RUNX1 inhibitor for ocular drug deliver | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2025-10-14 | — | — | US | claimed |
| US-20250313647-A1 | MUTANT AND MISLOCALIZED CELL SURFACE NUCLEOPHOSMIN 1 AS A DIAGNOSTIC AND THERAPEUTIC TARGET OF HUMAN DISEASE | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-10-09 | — | — | US | claimed |
| EP-4580677-A2 | SARS-COV2 ANTIBODIES AND USES THEREOF | Invivyd, Inc. (US) | 2025-07-09 | — | — | EP | claimed |
| WO-2025051818-A1 | METHODS FOR THE TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION | THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW (GB) | 2025-03-13 | — | — | WO | claimed |
| EP-4514857-A2 | ANTI-NUCLEOPHOSMIN 1 ANTIBODY AND ANTIBODY CONJUGATE COMBINATION THERAPIES | The Children's Medical Center Corporation (US) | 2025-03-05 | — | — | EP | claimed |
| EP-4514858-A2 | MUTANT AND MISLOCALIZED CELL SURFACE NUCLEOPHOSMIN 1 AS A DIAGNOSTIC AND THERAPEUTIC TARGET OF HUMAN DISEASE | The Children's Medical Center Corporation (US) | 2025-03-05 | — | — | EP | claimed |
| EP-4505179-A2 | SARS-COV2 ANTIBODIES AND USES THEREOF | Invivyd, Inc. (US) | 2025-02-12 | — | — | EP | claimed |
| EP-3672590-B1 | METHODS FOR INDUCING HEMATOPOIETIC STEM CELL SPECIFICITY | CHILDRENS MEDICAL CT CORP (US) | 2025-02-12 | — | — | EP | claimed |
| EP-4138853-A1 | METHODS AND MATERIALS FOR TREATMENT OF FIBROSIS | The Schepens Eye Research Institute, Inc. (US) | 2023-03-01 | — | — | EP | claimed |
| US-11583497-B2 | Nano-emulsion of CBFß-RUNX1 inhibitor for ocular drug delivery | THE SCHEPENS EYE RESEARCH INSTITUTE, INC. (US) | 2023-02-21 | — | — | US | claimed |
| US-20220341915-A1 | LUNG FIBROSIS MODEL AND METHODS OF USING THE SAME | DUKE UNIVERSITY (US) | 2022-10-27 | — | — | US | claimed |
| WO-2022170126-A2 | COMPOUNDS SPECIFIC TO CORONAVIRUS S PROTEIN AND USES THEREOF | ADAGIO THERAPEUTICS, INC. (US) | 2022-08-11 | — | — | WO | claimed |
| EP-4034142-A1 | LUNG FIBROSIS MODEL AND METHODS OF USING THE SAME | Duke University (US) | 2022-08-03 | — | — | EP | claimed |
| US-20220184109-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ABERRANT ANGIOGENESIS | MASSACHUSETTS EYE AND EAR INFIRMARY | 2022-06-16 | — | — | US | claimed |
| US-11229662-B2 | Compositions and methods for the treatment of aberrant angiogenesis | THE SCHEPENS EYE RESEARCH INSTITUTE, INC. (US) | 2022-01-25 | — | — | US | claimed |
| WO-2018215999-A1 | SELECTIVE DESTRUCTION OF CELLS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2018-11-29 | — | — | WO | claimed |
| WO-1997032587-A1 | METHODS FOR TREATING VIRAL INFECTIONS | DANA-FARBER CANCER INSTITUTE (US) | 1997-09-12 | — | — | WO | claimed |
| US-5641773-A | ADMINISTERING COMBINATION OF TAT INHIBITOR AND NF-KB INHIBITOR | DANA-FARBER CANCER INSTITUTE (US) | 1997-06-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11229662-B2 | Compositions and methods for the treatment of aberrant angiogenesis | VEGFA, PGF, FLT4 | KMT2A 4044/4885MEN1 3310/4885PDE4D 1454/4885 |
| US-12440443-B2 | Nano-emulsion of CBFβ-RUNX1 inhibitor for ocular drug deliver | RUNX1, CBFB, IKZF1 | KMT2A 518/4885MEN1 3044/4885PDE4D 3596/4885 |
| US-20220184109-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ABERRANT ANGIOGENESIS | VEGFA, PGF, FLT4 | KMT2A 4044/4885MEN1 3310/4885PDE4D 1454/4885 |
| US-12613236-B2 | Lung fibrosis model and methods of using the same | FN1, ACVR1, DSP | KMT2A 4758/4885MEN1 3141/4885PDE4D 512/4885 |
| US-11583497-B2 | Nano-emulsion of CBFß-RUNX1 inhibitor for ocular drug delivery | RUNX1, CBFB, IKZF1 | KMT2A 507/4885MEN1 2738/4885PDE4D 3794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.